Oculis Holding AG OCS
NASDAQ OCS
$12.17 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Oculis Holding AG (OCS) Cash from Operations (2022 - 2026)

Oculis Holding AG (OCS) posted quarterly Cash from Operations of 19585420.81 for Q1 2026, up 7.14% year-over-year from 18280015.07 in Q1 2025, and up 6.16% quarter-over-quarter from 20870763.3 in Q4 2025.

Analysis

Oculis Holding AG (OCS) Cash from Operations (2022 - 2026) Analysis & Trends

Oculis Holding AG's Cash from Operations history runs 5 years deep, the most recent figure standing at 19585420.81 for Q1 2026.

  • In Q1 2026, Cash from Operations rose 7.14% year-over-year to 19585420.81; the TTM figure through Mar 2026 stood at 78056596.89 (down 28.13% YoY), while the FY2025 annual figure was 79971143.7, down 43.82% from the prior year.
  • Cash from Operations for Q1 2026 stood at 19585420.81, up from 20870763.3 in the prior quarter.
  • The five-year high for Cash from Operations was 6781397.15 in Q4 2022, with the low at 21091606.91 in Q1 2025.
  • The 5-year median for Cash from Operations is 15718761.35 (2024), against an average of 15322007.63.
  • The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 136.21% in 2023, then gained 24.15% in 2024.
  • Oculis Holding AG's Cash from Operations stood at 6781397.15 in 2022, then slumped by 136.21% to 16018579.72 in 2023, then gained by 24.15% to 12150358.55 in 2024, then sank by 71.77% to 20870763.3 in 2025, then grew by 6.16% to 19585420.81 in 2026.
  • Business Quant data shows OCS's Cash from Operations at 19585420.81 in Q1 2026, 20870763.3 in Q4 2025, and 16773969.47 in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.13 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 813.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -526.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -387.32 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 462.82 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 326.72 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 728.46 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -88.83 Mn
10 Oculis Holding AG 634.75 Mn 345.87 Mn - -25.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -25.60 Mn
Mar 31, 2026 -19.59 Mn
Dec 31, 2025 -20.87 Mn
Sep 30, 2025 -16.77 Mn
Jun 30, 2025 -20.83 Mn
Mar 31, 2025 -21.09 Mn
Dec 31, 2024 -12.15 Mn
Sep 30, 2024 -12.48 Mn
Jun 30, 2024 -15.19 Mn
Mar 31, 2024 -15.72 Mn
Dec 31, 2023 -16.02 Mn
Sep 30, 2023 -13.56 Mn
Jun 30, 2023 -14.71 Mn
Mar 31, 2023 -16.89 Mn
Dec 31, 2022 -6.78 Mn
Sep 30, 2022 -7.17 Mn